BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hemgenix (etranacogene dezaparvovec) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Hemgenix (etranacogene dezaparvovec)\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06003387-10914@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281004
DTEND;VALUE=DATE:20281005
SUMMARY:Hemgenix (etranacogene dezaparvovec): Phase 3 readout est. (NCT0600
 3387)
DESCRIPTION:Hemgenix (etranacogene dezaparvovec)\, phase 3\, Hemophilia B.\
 nStudy: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene The
 rapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus 
 Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)\nEstimated primary comple
 tion: 4 October 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /etranacogene-dezaparvovec#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06003387
URL:https://assetmemo.bio/drug/etranacogene-dezaparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
